Innovent\'s NDA Filing for Humira Biosimilar Accepted in China

Innovent's NDA Filing for Humira Biosimilar Accepted in China

Innovent Biologics of Suzhou reported that China regulators have accepted its filing of a new drug application for IBI303, a biosimilar to Humira (adalimumab). It is Innovent's second NDA accepted by the NMPA -- the first is its anti-PD-L1 candidate (IBI308).  IBI303 is a recombinant human anti-TNF-α monoclonal antibody aimed at ankylosing spondylitis (AS), rheumatoid arthritis (RA) and psoriasis. Innovent said IBI303 will offer a high-quality and affordable alternative to branded Humira in China. More details....

Stock Symbol: (HK: 1801)

Share this with colleagues:

Original Article: Innovent's NDA Filing for Humira Biosimilar Accepted in China

More From BioPortfolio on "Innovent's NDA Filing for Humira Biosimilar Accepted in China"